It's been nearly two years since Elevidys, a gene therapy for Duchenne MD developed by Sarepta Therapeutics, was approved by ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first ...

We recently published a list of the 11 Most Promising Long-Term Stocks According to Analysts. In this article, we are going ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") for ...

Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major ...

Shares of gene therapy companies — including Sarepta Therapeutics — got a lift Monday after FDA's Marty Makary laid out his plans.